| Predicted Trait | |
| Reported Trait | Psoriatic arthritis |
| Mapped Trait(s) | psoriatic arthritis (EFO_0003778) |
| Score Construction | |
| PGS Name | wGRS_PsA |
| Development Method | |
| Name | GWAS-significant variants, HLA-specific significant variants. |
| Parameters | SNPs within candidate risk genes shown to be associated with Psoriasis only (PsO) or Psoriatic Arthritis (PsA) in large cohorts or genome-wide association studies. |
| Variants | |
| Original Genome Build | hg19 |
| Number of Variants | 11 |
| Effect Weight Type | log(OR) |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000111 |
| Citation (link to publication) | Smith MP et al. J Psoriasis Psoriatic Arthritis (2020) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 13,177 individuals (100%) |
| PGS Evaluation | Not Reported: 100% 1 Sample Sets |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
GWAS Catalog: GCST003269 Europe PMC: 26626624 |
6,297 individuals | European | NR |
GWAS Catalog: GCST003270 Europe PMC: 26626624 |
6,880 individuals | European | NR |
Europe PMC: 25948071 |
NR | NR | NR |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000971 | PSS000490| Ancestry Not Reported| 543 individuals |
PGP000111 | Smith MP et al. J Psoriasis Psoriatic Arthritis (2020) |
Reported Trait: Psoriatic arthritis | — | AUROC: 0.562 [0.506, 0.618] | — | — | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000490 | Cases included physician-confirmed psoriatic arthritis (PsA). Controls inclded individuals with psoriasis with no history of joint symptoms (psoriasis only - PsO). | — | [
|
— | NR | — | NR | — |